These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 28157069)

  • 1. Delayed de-induction of CYP2C9 compared to CYP3A after discontinuation of rifampicin: Report of two cases
.
    Shibata S; Takahashi H; Baba A; Takeshita K; Atsuda K; Matsubara H; Echizen H
    Int J Clin Pharmacol Ther; 2017 May; 55(5):449-452. PubMed ID: 28157069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rifampicin-warfarin interaction leading to macroscopic hematuria: a case report and review of the literature.
    Martins MA; Reis AM; Sales MF; Nobre V; Ribeiro DD; Rocha MO; Ribeiro AL
    BMC Pharmacol Toxicol; 2013 May; 14():27. PubMed ID: 23641931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variations in prothrombin time-international normalized ratio caused by drug-drug interaction in patients receiving warfarin: A retrospective observational study.
    Shiraishi C; Hirai T; Fujita S; Dohi K; Iwamoto T
    Int J Clin Pharmacol Ther; 2023 Apr; 61(4):139-147. PubMed ID: 36633369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S-Warfarin Limited Sampling Models to Estimate Area Under the Concentration Versus Time Curve for Cytochrome P450 2C9 Baseline Activity and After Induction.
    Chang AT; Bertino JS; Nafziger AN; Kashuba AD; Turpault S; Lewis LD; Ma JD
    Ther Drug Monit; 2016 Jun; 38(3):383-7. PubMed ID: 26818625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Difficulties in anticoagulation management during coadministration of warfarin and rifampin.
    Lee CR; Thrasher KA
    Pharmacotherapy; 2001 Oct; 21(10):1240-6. PubMed ID: 11601670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.
    Bolton AE; Peng B; Hubert M; Krebs-Brown A; Capdeville R; Keller U; Seiberling M
    Cancer Chemother Pharmacol; 2004 Feb; 53(2):102-6. PubMed ID: 14605865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 2: Prediction of Decreased Substrate Exposure After Rifabutin or Carbamazepine.
    Lutz JD; Kirby BJ; Wang L; Song Q; Ling J; Massetto B; Worth A; Kearney BP; Mathias A
    Clin Pharmacol Ther; 2018 Dec; 104(6):1191-1198. PubMed ID: 29569712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.
    Shumaker RC; Aluri J; Fan J; Martinez G; Thompson GA; Ren M
    Clin Drug Investig; 2014 Sep; 34(9):651-9. PubMed ID: 25022720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Describing the profile of patients on concurrent rifampin and warfarin therapy in western Kenya: a case series.
    Maina MW; Pastakia SD; Manji I; Kirui N; Kirwa C; Karwa R
    Drugs R D; 2013 Sep; 13(3):191-7. PubMed ID: 23982688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: an open-label, prospective study of long-term administration in adults.
    Muszkat M; Bialer O; Blotnick S; Adar L; Xie HG; Ufer M; Cascorbi I; Caraco Y
    Clin Ther; 2010 Feb; 32(2):347-56. PubMed ID: 20206792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probable warfarin and dapsone interaction.
    Truong T; Haley J
    Clin Appl Thromb Hemost; 2012; 18(1):107-9. PubMed ID: 21890570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
    Beinema M; Brouwers JR; Schalekamp T; Wilffert B
    Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs.
    Nomoto M; Zamora CA; Schuck E; Boyd P; Chang MK; Aluri J; Siu YA; Lai WG; Yasuda S; Ferry J; Rege B
    Br J Clin Pharmacol; 2018 May; 84(5):952-960. PubMed ID: 29341245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of simvastatin on warfarin disposition and dose requirements.
    Sconce EA; Khan TI; Daly AK; Wynne HA; Kamali F
    J Thromb Haemost; 2006 Jun; 4(6):1422-4. PubMed ID: 16706996
    [No Abstract]   [Full Text] [Related]  

  • 15. A comparative study for detecting CYP3A induction by CYP3A probe drugs and endogenous markers in cynomolgus monkeys.
    Tahara H; Watanabe M; Hasegawa M
    Biopharm Drug Dispos; 2019 Feb; 40(2):81-93. PubMed ID: 30724384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic Interaction of Rifampicin with Oral Versus Intravenous Anticancer Drugs: Challenges, Dilemmas and Paradoxical Effects Due to Multiple Mechanisms.
    Srinivas NR
    Drugs R D; 2016 Jun; 16(2):141-8. PubMed ID: 27098526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of Tecarfarin and Warfarin in Patients with Severe Chronic Kidney Disease.
    Albrecht D; Turakhia MP; Ries D; Marbury T; Smith W; Dillon D; Milner PG; Midei MG
    Thromb Haemost; 2017 Nov; 117(11):2026-2033. PubMed ID: 28933798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effects of Weak and Strong CYP3A Induction by Rifampicin on the Pharmacokinetics of Five Progestins and Ethinylestradiol Compared to Midazolam.
    Wiesinger H; Klein S; Rottmann A; Nowotny B; Riecke K; Gashaw I; Brudny-Klöppel M; Fricke R; Höchel J; Friedrich C
    Clin Pharmacol Ther; 2020 Oct; 108(4):798-807. PubMed ID: 32275771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
    Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
    Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Warfarin and bosentan interaction in a patient with pulmonary hypertension secondary to bilateral pulmonary emboli.
    Spangler ML; Saxena S
    Clin Ther; 2010 Jan; 32(1):53-6. PubMed ID: 20171411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.